Chengdu Beite's 3 major new products will be approved

Recently, Chengdu Better (including its subsidiaries) has 3 new generic drugs that have been classified for production and entered the administrative approval stage, namely Futhiaxetine Hydrobromide Tablets, Lenvatinib Mesylate Capsules and Ipratropium Bromide.

Source: official website of the State Drug Administration

Lenvatinib is a multi-target receptor tyrosine kinase inhibitor developed by Eisai.

The original research product was approved to enter the domestic market in September 2018, breaking the long-term monopoly of sorafenib in the first-line liver cancer market.

The lenvatinib mesylate capsules of Zhengda Tianqing and Simcere Pharmaceuticals were approved for the market on the same day, and they were tied for the first imitation; the products of Nanjing Zhengda Tianqing and Qilu Pharmaceuticals were also approved one after another, and Chengdu Beite’s products entered "Under approval" status, is expected to win the fifth domestically produced company

Source: official website of the State Drug Administration

Futhiaxetine is a serotonin (5-HT) reuptake inhibitor developed by Lingbei.

At present, 7 domestic companies have submitted applications for the listing of vothiaxetine hydrobromide tablets.

Source: official website of the State Drug Administration

Ipratropium bromide is a highly selective M receptor blocker, which is suitable for the relief of chronic asthmatic bronchitis

In addition to the original research products, currently only the two companies of China Resources Double Crane and Beijing Hyderun are on the market for ipratropium bromide aerosol, and Sichuan Prime (a subsidiary of Bettertech) is expected to become the third domestic company

Source: Mi Nei.

Note: The statistics are as of October 26.